Tyra BiosciencesTYRA
TYRA
About: Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Employees: 60
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
366% more call options, than puts
Call options by funds: $233K | Put options by funds: $50K
35% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 31
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
4.84% more ownership
Funds ownership: 96.07% [Q4 2024] → 100.91% (+4.84%) [Q1 2025]
4% more funds holding
Funds holding: 113 [Q4 2024] → 117 (+4) [Q1 2025]
20% less funds holding in top 10
Funds holding in top 10: 5 [Q4 2024] → 4 (-1) [Q1 2025]
26% less capital invested
Capital invested by funds: $676M [Q4 2024] → $500M (-$176M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
188%
upside
Avg. target
$32
202%
upside
High target
$33
216%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler Allison Bratzel | 216%upside $33 | Overweight Assumed | 21 May 2025 |
HC Wainwright & Co. Mitchell Kapoor | 188%upside $30 | Buy Reiterated | 31 Mar 2025 |
Financial journalist opinion
Neutral
PRNewsWire
1 month ago
Tyra Biosciences to Participate at Upcoming Investor Conferences
CARLSBAD, Calif. , May 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the following investor conferences: Bank of America Global Healthcare Conference, May 13-15, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Tuesday, May 13, 2025, at 5:15 PM PT Location: Las Vegas, NV Jefferies Global Healthcare Conference, June 3-5, 2025 Format: One-on-one investor meetings Location: New York, NY UBS Biotech 1x1 Symposium, June 24, 2025 Format: One-on-one investor meetings Location: New York, NY A live and archived webcast of the fireside chat will be available via the For Investors page on the Investor section of the TYRA website.
Neutral
PRNewsWire
1 month ago
Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights
- BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment - - Initiated patient dosing in SURF431 study of TYRA-430 for hepatocellular carcinoma (HCC) - - Cash, cash equivalents, and marketable securities of $318.9 million at Q1 2025; runway through at least 2027 - CARLSBAD, Calif. , May 8, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate progress.
Neutral
PRNewsWire
2 months ago
Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights
- Three INDs cleared by US FDA for TYRA's proprietary precision small molecules - - TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC), BEACH301 for pediatric achondroplasia (ACH) and SURF301 for metastatic urothelial cancer (mUC) - - Cash, cash equivalents, and marketable securities of $341.4 million at YE 2024; runway through at least 2027 - CARLSBAD, Calif. , March 27, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted recent corporate progress.
Neutral
PRNewsWire
4 months ago
Tyra Biosciences to Present at Upcoming Investor Conferences
CARLSBAD, Calif. , Feb. 11, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: Oppenheimer 35th Annual Healthcare Life Sciences Conference, February 11-12, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Wednesday, February 12, 2025, at 2:00 PM ET Location: Virtual TD Cowen 45th Annual Healthcare Conference, March 3-5, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Monday, March 3, 2025, at 9:50 AM ET Location: Boston Jefferies Biotech on the Beach Summit, March 11-12, 2025 Format: One-on-one investor meetings Location: Miami Barclays 27th Annual Global Healthcare Conference, March 11-13, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Wednesday, March 12, 2025, at 8:30 AM ET Location: Miami A live and archived webcast of the fireside chats will be available via the For Investors page on the Investor section of the TYRA website.
Neutral
PRNewsWire
4 months ago
Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium
CARLSBAD, Calif. , Jan. 22, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that two abstracts were accepted for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI), taking place January 23-25, 2025, in San Francisco, CA.
Neutral
PRNewsWire
5 months ago
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
-TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC- -First patient expected to be dosed in SURF302 in Q2 2025- CARLSBAD, Calif.
Neutral
24/7 Wall Street
6 months ago
Post-Election Insider Buying in These 6 Stocks Is Huge
24/7 Wall St. Insights As we race toward the end of the year, the past week brought some huge insider share purchases.
Neutral
PRNewsWire
7 months ago
Tyra Biosciences to Present at Upcoming Investor Conferences
CARLSBAD, Calif. , Nov. 13, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: Jefferies London Healthcare Conference, November 19-21st, 2024: Todd Harris, CEO of TYRA, will participate in a fireside chat on Tuesday, November 19th, at 2:00 pm GMT.
Neutral
PRNewsWire
7 months ago
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights
- Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study - - IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301) - - Strengthened leadership with appointment of Doug Warner, MD as Chief Medical Officer - - Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif. , Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended September 30, 2024, and highlighted recent corporate progress.
Neutral
PRNewsWire
7 months ago
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)
– TYRA-300 is the first oral FGFR-3 selective inhibitor to be well-tolerated in clinical studies – – First child with achondroplasia expected to be dosed in Q1 2025 – CARLSBAD, Calif. , Oct. 28, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for TYRA-300 allowing the company to proceed with a Phase 2 clinical trial of TYRA-300 for children with achondroplasia (BEACH301).
Charts implemented using Lightweight Charts™